Cardiovascular disease and risk factors in Iraqi cancer patients: a cross-sectional study
Cancer and cardiovascular disease
DOI:
https://doi.org/10.29409/zeze0408Keywords:
cardiovascular diseases, cancer, myocardial infarction, angina, hypertension, diabetes mellitus, frequency, incidenceAbstract
Background: Cardiovascular diseases and cancer are major causes of mortality worldwide. Comorbidities among cancer patients significantly influence prognosis and quality of life. These comorbidities, including cardiovascular disease, may result from underlying pathology similar to that of noncancer patients, chemotherapy, or direct tumor extension. Our study aims to estimate the burden of cardiovascular diseases among cancer patients in our community.
Methods: This was an observational cross-sectional study conducted at Basra Oncology Center and Basra Hematology Center. In this study, adult patients with different types of cancer, including solid and hematological malignancies, were included. The investigators extracted data from the medical records of the patients, including demographic data, past medical history, cancer type and stage, type of treatment (chemotherapy or radiotherapy), and history of cardiovascular diseases (ischemic heart disease, heart failure, valvular heart disease, pericardial disease, deep vein thrombosis, pulmonary embolism, cerebrovascular accidents, hypertension, hyperlipidemia, and diabetes mellitus).
Results: We randomly enrolled 250 adult patients, including 173 females (average age 53.4 years, range 20-87). Breast cancer was the most common type, followed by gastrointestinal, genitourinary, lung, hematological, and brain tumors. Among the 250 patients, 51 (20.4%) had cardiovascular diseases, with ischemic heart disease being the most frequent, followed by venous thromboembolism, deep vein thrombosis, arrhythmia, heart failure, and valvular diseases. Additionally, 207 patients (82.8%) had cardiovascular risk factors, with hypertension being the most prevalent risk factor.
Conclusion: The burden of cardiovascular disease and risk factors significantly present across all types of cancer. Early diagnosis and management of cardiovascular disease in cancer patients are needed to improve prognosis.
References
1. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 8;388(10053):1459-1544. doi: 10.1016/S0140-6736(16)31012-1.
2. Cho H, Mariotto AB, Mann BS, Klabunde CN, Feuer EJ. Assessing non-cancer-related health status of US cancer patients: other-cause survival and comorbidity prevalence. Am J Epidemiol. 2013;178(3):339–49
3. Sarfati D, Koczwara B, Jackson C. The impact of comorbidity on cancer and its treatment. CA Cancer J Clin. 2016;66(4):337-350. doi:10.3322/caac.21342
4. Al-Kindi SG, Oliveira GH. Prevalence of Preexisting Cardiovascular Disease in Patients With Different Types of Cancer: The Unmet Need for Onco-Cardiology. Mayo Clin Proc. 2016;91(1):81-83.
5. Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, et al. Annual report to the nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 2014; 120: 1290 – 1314
6. Sueta D, Hokimoto S, Utsunomiya D, Tabata N, Akasaka T, Sakamoto K, et al. New aspects of onco-cardiology. Int J Cardiol 2016; 206: 68 – 70.
7. Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MSV, et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol 2017; 70: 926 – 938
8. Bloom MW, Hamo CE, Cardinale D, Ky B, Nohria A, Baer L, et al. Cancer therapy-related cardiac dysfunction and heart failure. Part 1: Definitions, pathophysiology, risk factors, and imaging. Circ Heart Fail 2016; 9: e002661.
9. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for Cancer Treatments and Cardiovascular Toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016;
37: 2768 – 2801.
10. Okura Y, Takayama T, Ozaki K, Tanaka H, Seki H, Takenouchi T, et al. Burden of cardiovascular disease on Japanese cancer patients and survivors: A single cancer-center study in Niigata City. Int J Clin Oncol 2019; 24: 196 – 210.
11. Liu D, Ma Z, Yang J, Zhao M, Ao H, Zheng X, et al. Prevalence and prognosis significance of cardiovascular disease in cancer patients: a population-based study. Aging (Albany NY). 2019 Sep 9;11(18):7948.
12. Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, et al. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014 May 1;120(9):1290-314.
13. Mamas, M.A., Sperrin, M., Watson, M.C., Coutts, A., Wilde, K., Burton, C., Kadam, et al. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. Eur J Heart Fail, 19: 1095-1104.
14. Park, C., Han, S., Litten, K. P., Mehta, S., & Ng, B. P. Prevalence of primary and secondary hypertension among hospitalized patients with cancer in the United States. Chronic Illness. https://doi.org/10.1177/17423953231196613
15. Gue YX, Bisson A, Bodin A, Herbert J, Lip GYH, Fauchier L. Breast cancer and incident cardiovascular events: A systematic analysis at the nationwide level. Eur J Clin Invest. 2022; 52:e13754
Additional Files
Received
Revised
Accepted
Published
Data Availability Statement
The data supporting the findings of this study are available from the corresponding author upon reasonable request. The data are not publicly available due to privacy and confidentiality considerations related to patient information.
Issue
Section
License
Copyright (c) 2026 Iraqi Journal of Cancer and Medical Genetics
This work is licensed under a Creative Commons Attribution 4.0 International License.
